Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2010, Article ID 957549, 8 pages
Clinical Study

Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?

1Division of Pharmacy Practice and Administration, University of Missouri-Kansas City, Kansas City, MO 64108, USA
2Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Avenue Campus Box 8126, St. Louis, MO 63110, USA

Received 4 August 2010; Accepted 26 September 2010

Academic Editor: P. S. Randhawa

Copyright © 2010 Karen L. Hardinger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared the safety and efficacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days ( ) versus 2 mg/kg for 3 days ( ), in a retrospective, cohort study. Results. Two-year rejection-free survival was 95% in each group ( ). Renal function and infection rates were similar. The incidence of leucopenia was similar, although the 2 mg/kg group was more likely to be thrombocytopenic on day 2 (4% versus 28%, ). Length of stay tended to be longer for the 1.5 mg/kg group ( versus days ). A cost savings of $920 per patient for rATG were seen in the 2 mg/kg group ( ). Conclusions. Shorter, more intense dosing of rATG is safe and effective. The 3-day dose strategy resulted in a clinically shorter length of stay and may result in cost savings.